Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Should l Buy IBRX?
Source: Newsfilter
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.780
Low
5.00
Averages
7.33
High
9.00
Current: 7.780
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that ImmunityBio executives made false and misleading statements during the class period, resulting in investor losses when the true facts emerged, which could negatively impact the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential misconduct in the company's promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its advertisements and podcast content were misleading, particularly the claim that Anktiva could cure all cancers, which lacked supporting data, resulting in a more than 21% drop in the company's stock price on March 24, 2026.
- Market Impact: Following the FDA's warning, ImmunityBio's market capitalization plummeted by nearly $2 billion in a short period, underscoring the regulatory scrutiny on biopharmaceutical companies' promotional activities and its direct impact on investor confidence.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to file claims, indicating that the legal risks faced by the company could further exacerbate uncertainties in its market performance.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, which misled investors about the company's prospects.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is involved in a class action from January 19, 2026, to March 24, 2026, where executives allegedly overstated Anktiva's capabilities, leading to misleading positive statements about the company's business, with a lead plaintiff deadline of May 26, 2026.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) is facing a class action for the period from February 7, 2025, to February 12, 2026, with allegations of failing to disclose risks of reduced advertising revenues and overstating its ability to manage U.S. tariffs, which could lead to imminent restructuring, with a lead plaintiff deadline of May 29, 2026.
- Legal Consultation Information: Investors suffering losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights and participate in the class actions, ensuring their interests are protected through professional legal guidance.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to significant financial losses.
- FDA Warning Impact: A warning letter from the FDA to CEO Richard Adcock, made public on March 24, 2026, highlighted misleading advertisements for Anktiva, indicating violations of the Federal Food, Drug, and Cosmetic Act and raising public health concerns.
- Stock Price Drop: Following the news, ImmunityBio's stock price fell by 21%, losing $1.98 per share to close at $7.42, reflecting market concerns regarding the company's compliance and future outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio (IBRX) is facing a class action lawsuit for making false statements between January 19 and March 24, 2026, with investors having until May 26, 2026, to seek lead plaintiff status, highlighting significant legal compliance risks for the company.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter accusing ImmunityBio executives of making inaccurate claims about their lead biologic product, Anktiva, on a podcast, resulting in a 21.12% drop in stock price, indicating a severe loss of market confidence in the company's prospects.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal support, reflecting investor concerns over corporate governance and transparency, which may influence future investment decisions.
- Legal Consequences: The lawsuit alleges that ImmunityBio made materially misleading statements regarding its business operations, and an unfavorable ruling could lead to substantial financial liabilities, further impacting the company's financial stability and market reputation.
See More
ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead product, ANKTIVA, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file papers by May 26, 2026, with the lead plaintiff representing other class members in directing the litigation, although non-lead plaintiffs can still share in any recovery without taking action.
- Transparent Fee Structure: The representation operates on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages broader participation from affected shareholders.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” demonstrating its expertise and credibility in securities litigation through successful handling of hundreds of class actions.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that ImmunityBio executives made false and misleading statements during the class period, resulting in investor losses when the true facts emerged, which could negatively impact the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential misconduct in the company's promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its advertisements and podcast content were misleading, particularly the claim that Anktiva could cure all cancers, which lacked supporting data, resulting in a more than 21% drop in the company's stock price on March 24, 2026.
- Market Impact: Following the FDA's warning, ImmunityBio's market capitalization plummeted by nearly $2 billion in a short period, underscoring the regulatory scrutiny on biopharmaceutical companies' promotional activities and its direct impact on investor confidence.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to file claims, indicating that the legal risks faced by the company could further exacerbate uncertainties in its market performance.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, which misled investors about the company's prospects.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is involved in a class action from January 19, 2026, to March 24, 2026, where executives allegedly overstated Anktiva's capabilities, leading to misleading positive statements about the company's business, with a lead plaintiff deadline of May 26, 2026.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) is facing a class action for the period from February 7, 2025, to February 12, 2026, with allegations of failing to disclose risks of reduced advertising revenues and overstating its ability to manage U.S. tariffs, which could lead to imminent restructuring, with a lead plaintiff deadline of May 29, 2026.
- Legal Consultation Information: Investors suffering losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights and participate in the class actions, ensuring their interests are protected through professional legal guidance.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to significant financial losses.
- FDA Warning Impact: A warning letter from the FDA to CEO Richard Adcock, made public on March 24, 2026, highlighted misleading advertisements for Anktiva, indicating violations of the Federal Food, Drug, and Cosmetic Act and raising public health concerns.
- Stock Price Drop: Following the news, ImmunityBio's stock price fell by 21%, losing $1.98 per share to close at $7.42, reflecting market concerns regarding the company's compliance and future outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio (IBRX) is facing a class action lawsuit for making false statements between January 19 and March 24, 2026, with investors having until May 26, 2026, to seek lead plaintiff status, highlighting significant legal compliance risks for the company.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter accusing ImmunityBio executives of making inaccurate claims about their lead biologic product, Anktiva, on a podcast, resulting in a 21.12% drop in stock price, indicating a severe loss of market confidence in the company's prospects.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal support, reflecting investor concerns over corporate governance and transparency, which may influence future investment decisions.
- Legal Consequences: The lawsuit alleges that ImmunityBio made materially misleading statements regarding its business operations, and an unfavorable ruling could lead to substantial financial liabilities, further impacting the company's financial stability and market reputation.
See More
ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead product, ANKTIVA, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file papers by May 26, 2026, with the lead plaintiff representing other class members in directing the litigation, although non-lead plaintiffs can still share in any recovery without taking action.
- Transparent Fee Structure: The representation operates on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages broader participation from affected shareholders.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” demonstrating its expertise and credibility in securities litigation through successful handling of hundreds of class actions.
See More
